Genetics Meets Drug Discovery


Cancer is a multistep process that arises from a series of genetic and epigenetic events. With recent technological advances there has been a burst in genome sequencing and epigenetic studies revealing a plethora of alterations that may contribute to cancer. However, the great challenge for the cancer research community is the systematic functional characterization of these genetic and epigenetic events to assess their role in cancer initiation and progression. In addition, the emerging role of the tumour microenvironment as well as the immune system in cancer development and response to therapies has made in vivo models critical to confirm and explore novel therapies targeting non-cell autonomous mechanisms.

The goal of our Research Topic is to highlight the breakthroughs in the effective use of genetically modified mouse models (GEMMs) and other in vivo and in vitro models, with a particular emphasis on genome editing that has revolutionized cancer genetics. Challenges, potential applications as well as limitations of such systems will be addressed.

We will include the following topics:

· Overview of traditional approaches to functionally characterize cancer genes

· In vitro modeling of genetic variants using ZNFs, TALENs and CRISPR/Cas9

· Modeling of genetic events in the germline

· Somatic genome engineering with CRISPR/Cas9

· CRISPR/Cas9-based effectors

· Bioinformatic tools to predict CRISPR/Cas9 specificity

· CRISPR/Cas9-based genetic screens

All type of articles may be submitted for this Research Topic. Submissions can be done either at Editorial tracking system or through mail to

Media Contact:

Kathy Andrews
Managing Editor
Journal of Genomics & Gene Study